What is the efficacy of prasugrel compared with clopidogrel in patients with SIHD?
Prasugrel has not been tested or approved for use in patients with SIHD. In TRITON-TIMI (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis In Myocardial Infarction) 38, there was a 19% reduction in RR of the primary efficacy endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) but an increased risk of bleeding with prasugrel compared with clopidogrel in ACS patients scheduled for percutaneous revascularization.746 Clinical trials evaluating prasugrel in patients with SIHD have not been conducted.